

QUANTITY LIMIT CRITERIA

DRUG CLASS	ANTICHOLINERGIC, COMBINATION, AND MAST CELL STABILIZER ORAL INHALATION
BRAND NAME (generic)	ATROVENT HFA (ipratropium)
	COMBIVENT RESPIMAT (ipratropium/albuterol)
	(cromolyn sodium inhalation solution)
	INCRUSE ELLIPTA (umeclidinium)
	(ipratropium bromide inhalation solution)
	(ipratropium bromide/albuterol sulfate inhalation solution)
	LONHALA MAGNAIR (glycopyrrolate inhalation solution)
	SPIRIVA HANDIHALER (tiotropium)
	SPIRIVA RESPIMAT (tiotropium)
	TUDORZA PRESSAIR (aclidinium)
	YUPELRI (revefenacin inhalation solution)

Status: CVS Caremark® Criteria
Type: Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Atrovent HFA

Anticholinergic, Combination, Mast Cell Stabilizer Oral Inhalation Limit Policy 139-H 10-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428| 021423

Atrovent HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Combivent Respimat

Combivent Respimat is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta₂-adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.

Cromolyn Sodium Inhalation Solution

Cromolyn sodium inhalation solution USP is a prophylactic agent indicated in the management of patients with bronchial asthma. In patients whose symptoms are sufficiently frequent to require a continuous program of medication, cromolyn sodium inhalation solution USP is given by inhalation on a regular daily basis. The effect of cromolyn sodium is usually evident after several weeks of treatment, although some patients show an almost immediate response. In patients who develop acute bronchoconstriction in response to exposure to exercise, toluene diisocyanate, environmental pollutants, etc., cromolyn sodium should be given shortly before exposure to the precipitating factor.

Incruse Ellipta

Incruse Ellipta is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Ipratropium Bromide Inhalation Solution

Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

Ipratropium Bromide / Albuterol Sulfate Inhalation Solution

Ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator.

Lonhala Magnair

Lonhala Magnair is indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Spiriva HandiHaler

Spiriva HandiHaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Spiriva HandiHaler is indicated to reduce exacerbations in COPD patients.

Spiriva Respimat

Maintenance Treatment of Chronic Obstructive Pulmonary Disease

Spiriva Respimat (tiotropium bromide) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Spiriva Respimat is indicated to reduce exacerbations in COPD patients.

Important Limitation of Use:

Spiriva Respimat is NOT indicated for the relief of acute bronchospasm.

Maintenance Treatment of Asthma

Spiriva Respimat is a bronchodilator indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older.

Important Limitation of Use:

Spiriva Respimat is NOT indicated for the relief of acute bronchospasm.

Tudorza Pressair

Tudorza Pressair (aclidinium bromide inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Anticholinergic, Combination, Mast Cell Stabilizer Oral Inhalation Limit Policy 139-H 10-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

Yupelri

Yupelri is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

INITIAL LIMIT QUANTITY				
Limits do not accumulate together; patient is allowed the maximum limit for each drug and strength				
Medication*	Maintenance Dose	Maximum Daily Dose	Package Size	1 Month Limit* 3 Month Limit*
Atrovent HFA (ipratropium)	2 inhalations four times daily	12 inhalations	200 inhalations per 12.9 gm canister	2 packages (12.9 gm each) / 25 days 6 packages (12.9 gm each) / 75 days
Combivent Respimat (ipratropium / albuterol)	1 inhalation four times daily	6 inhalations	120 inhalations per 4 gm cartridge	2 packages (4 gm each) / 25 days 6 packages (4 gm each) / 75 days
Cromolyn sodium inhalation solution	nebulization of 1 vial (2 mL) four times daily	4 vials (2 mL each)	60 vials (2 mL each) per carton	2 packages (120 vials x 2 mL) / 25 days 6 packages (360 vials x 2 mL) / 75 days
Incruse Ellipta (umeclidinium)	1 inhalation once daily	1 inhalation	30 blisters per inhaler	1 package (30 blisters) / 25 days 3 packages (90 blisters) / 75 days
Ipratropium bromide inhalation solution, 0.02%	nebulization of 1 vial (2.5 mL) three to four times daily	4 vials (2.5 mL each)	25 vials (2.5 mL each) per carton	5 packages (125 vials x 2.5 mL) / 25 days 15 packages (375 vials x 2.5 mL) / 75 days
			30 vials (2.5 mL each) per carton	4 packages (120 vials x 2.5 mL) / 25 days 12 packages (360 vials x 2.5 mL) / 75 days
			60 vials (2.5 mL each) per carton	2 packages (120 vials x 2.5 mL) / 25 days 6 packages (360 vials x 2.5 mL) / 75 days
Ipratropium bromide / albuterol sulfate inhalation solution	nebulization of 1 vial (3 mL) four times daily	6 vials (3 mL each)	30 vials (3 mL each) per carton	6 packages (180 vials x 3 mL) / 25 days 18 packages (540 vials x 3 mL) / 75 days
			60 vials (3mL each) per carton	3 packages (180 vials x 3mL) / 25 days 9 packages (540 vials x 3mL) / 75 days
Lonhala Magnair Starter Kit and Refill Kit (glycopyrrolate)	1 inhalation twice daily	2 inhalations	60 vials (1 mL each) (2 vials in each pouch, 30 pouches) per kit	1 package (60 vials x 1 mL) / 25 days 3 packages (180 vials x 1 mL) / 75 days
Spiriva HandiHaler (tiotropium)	2 inhalations of the powder contents of 1 capsule once daily	1 capsule	30 capsules per carton	1 package (30 capsules) / 25 days 3 packages (90 capsules) / 75 days
			90 capsules per carton	1 package (90 capsules) / 75 days
Spiriva Respimat (tiotropium)	2 inhalations once daily	2 inhalations	60 inhalations per 4 gm cartridge	1 package (4 gm) / 25 days 3 packages (4 gm each) / 75 days
Tudorza Pressair (aclidinium)	1 inhalation twice daily	2 inhalations	30 inhalations per inhaler	2 packages / 25 days 6 packages / 75 days
			60 inhalations per inhaler	1 package / 25 days 3 packages / 75 days

Anticholinergic, Combination, Mast Cell Stabilizer Oral Inhalation Limit Policy 139-H 10-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

Yupelri (revefenacin)	nebulization of 1 vial (3 mL) once daily	1 vial (3mL each)	30 vials (3 mL each) per carton	1 package (30 vials x 3 mL) / 25 days 3 packages (90 vials x 3 mL) / 75 days
<i>*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.</i>				

REFERENCES

1. Atrovent HFA [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; February 2020.
2. Combivent Respimat [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; December 2021.
3. Cromolyn Sodium Inhalation Solution [package insert]. Columbia, SC: Ritedose Pharmaceuticals, LLC; August 2023.
4. Incruse Ellipta [package insert]. Research Triangle Park, NC: GlaxoSmithKline; August 2020.
5. Ipratropium Bromide [package insert]. East Windsor, NJ: Aurobindo Pharma USA, Inc.; September 2022.
6. Ipratropium Bromide and Albuterol Sulfate [package insert]. East Windsor, NJ: Aurobindo Pharma USA, Inc.; August 2022.
7. Lonhala Magnair [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; August 2020.
8. Spiriva Handihaler [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; November 2021.
9. Spiriva Respimat [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; November 2021.
10. Tudorza Pressair [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2021.
11. Yupelri [package insert]. Morgantown, WV: Mylan Specialty L.P.; May 2022.